Kintara Therapeutics, Inc.
Pagina dedicata companiei Kintara Therapeutics, Inc. listata cu simbolul US.KTRA
Descriere companie[edit | ]
Kintara Therapeutics, Inc. (www.kintara.com) is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.
Grafic actiuni companie[edit | ]